Skip to Main Content

Skip Nav Destination

Letter| October 1, 2024

High-dose IV ascorbic acid therapy in CCUS patients with TET2 mutations

Zhuoer Xie,

Zhuoer Xie

Mayo Clinic, United States

https://orcid.org/0000-0003-1266-9804

Search for other works by this author on:

PubMed

Google Scholar

Jenna Fernandez,

Jenna Fernandez

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Terra L Lasho,

Terra L Lasho

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Christy M. Finke,

Christy M. Finke

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Michelle Amundson,

Michelle Amundson

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Kristen McCullough,

Kristen McCullough

Mayo Clinic, Rochester, Minnesota, United States

https://orcid.org/0000-0003-4252-2619

Search for other works by this author on:

PubMed

Google Scholar

Betsy LaPlant,

Betsy LaPlant

Mayo Clinic, Rochester, United States

Search for other works by this author on:

PubMed

Google Scholar

Abhishek A Mangaonkar,

Abhishek A Mangaonkar

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Naseema Gangat,

Naseema Gangat

Mayo Clinic, Rochester, Minnesota, United States

https://orcid.org/0000-0002-9104-6172

Search for other works by this author on:

PubMed

Google Scholar

Kaaren K Reichard,

Kaaren K Reichard

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Michelle Ann Elliott,

Michelle Ann Elliott

Mayo Clinic, Rochester, Minnesota, United States

Search for other works by this author on:

PubMed

Google Scholar

Thomas E. Witzig,

Thomas E. Witzig

Mayo Clinic, Rochester, Minnesota, United States

https://orcid.org/0000-0002-4215-6500

Search for other works by this author on:

PubMed

Google Scholar

Mrinal M. Patnaik

Mrinal M. Patnaik

Mayo Clinic, Rochester, Minnesota, United States

* Corresponding Author; email: patnaik.mrinal@mayo.edu

https://orcid.org/0000-0001-6998-662X

Search for other works by this author on:

PubMed

Google Scholar

Blood blood.2024024962.

https://doi.org/10.1182/blood.2024024962

This was a phase II trial, evaluating the safety/efficacy of high-dose IV-ascorbic acid in patients with TET2 mutant CCUS. Eight of 10 patients enrolled were eligible for response assessment. At week 20, there were no responses by IWG MDS criteria. NCT03418038

This content is only available as a PDF.

Copyright © 2024 American Society of Hematology

2024

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Sign in via your Institution

Supplemental data